Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1

Article  PubMed  PubMed Central  Google Scholar 

Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018

Article  PubMed  Google Scholar 

Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson’s disease. Mov Disord 33:900–908. https://doi.org/10.1002/mds.27340

Article  PubMed  Google Scholar 

Antonini A, Odin P, Schmidt P et al (2021) Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson’s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord 92:59–66. https://doi.org/10.1016/j.parkreldis.2021.10.009

Article  CAS  PubMed  Google Scholar 

Antonini A, D’Onofrio V, Guerra A (2023) Current and novel infusion therapies for patients with Parkinson’s disease. J Neural Transm. https://doi.org/10.1007/s00702-023-02693-8

Article  PubMed  Google Scholar 

Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson Disease: a review. JAMA 323:548–560. https://doi.org/10.1001/jama.2019.22360

Article  PubMed  Google Scholar 

Artusi CA, Dwivedi AK, Romagnolo A et al (2019) Association of Subthalamic Deep Brain Stimulation with Motor, Functional, and pharmacologic outcomes in patients with monogenic Parkinson Disease: a systematic review and Meta-analysis. JAMA Netw Open 2:e187800. https://doi.org/10.1001/jamanetworkopen.2018.7800

Article  PubMed  PubMed Central  Google Scholar 

Avenali M, Zangaglia R, Cuconato G et al (2024) Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry 95:309–315. https://doi.org/10.1136/jnnp-2023-332387

Article  PubMed  Google Scholar 

Benabid AL, Pollak P, Gervason C et al (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337:403–406. https://doi.org/10.1016/0140-6736(91)91175-t

Article  CAS  PubMed  Google Scholar 

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X

Article  CAS  PubMed  Google Scholar 

Bouthour W, Mégevand P, Donoghue J et al (2019) Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond. Nat Rev Neurol 15:343–352. https://doi.org/10.1038/s41582-019-0166-4

Article  PubMed  Google Scholar 

Bove F, Mulas D, Cavallieri F et al (2021) Long-term outcomes (15 years) after Subthalamic Nucleus Deep Brain Stimulation in patients with Parkinson Disease. Neurology. https://doi.org/10.1212/WNL.0000000000012246

Article  PubMed  PubMed Central  Google Scholar 

Brinker D, Smilowska K, Paschen S et al (2023) How to use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson’s Disease. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.13962

Article  PubMed  PubMed Central  Google Scholar 

Busk K, Nyholm D (2012) Long-term 24-h levodopa/carbidopa gel infusion in Parkinson’s disease. Parkinsonism Relat Disord 18:1000–1001. https://doi.org/10.1016/j.parkreldis.2012.04.010

Article  PubMed  Google Scholar 

Cif L, Hariz M (2017) Seventy years with the Globus Pallidus: pallidal surgery for Movement disorders between 1947 and 2017. Mov Disord 32:972–982. https://doi.org/10.1002/mds.27054

Article  PubMed  Google Scholar 

Cruse B, Morales-Briceño H, Chang FCF et al (2018) 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease. NPJ Parkinsons Dis 4:34. https://doi.org/10.1038/s41531-018-0070-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dafsari HS, Petry-Schmelzer JN, Ray-Chaudhuri K et al (2018) Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on location of active contacts. Brain Stimul 11:904–912. https://doi.org/10.1016/j.brs.2018.03.009

Article  PubMed  Google Scholar 

Davis KL, Edin HM, Allen JK (2010) Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord 25:474–480. https://doi.org/10.1002/mds.22999

Article  PubMed  Google Scholar 

Debove I, Paschen S, Amstutz D et al (2024) Management of Impulse Control and Related disorders in Parkinson’s Disease: An Expert Consensus. https://doi.org/10.1002/mds.29700. Mov Disord

Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908. https://doi.org/10.1056/NEJMoa060281

Article  CAS  PubMed  Google Scholar 

Deuschl G, Antonini A, Costa J et al (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the treatment of Parkinson’s Disease: I. Invasive therapies. Mov Disord 37:1360–1374. https://doi.org/10.1002/mds.29066

Article  PubMed  Google Scholar 

Fasano A, Fung VSC, Lopiano L et al (2019) Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol 19:50. https://doi.org/10.1186/s12883-019-1276-8

Article  PubMed  PubMed Central  Google Scholar 

Fasano A, Gurevich T, Jech R et al (2021) Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS Study. Mov Disord 36:1853–1862. https://doi.org/10.1002/mds.28596

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123

Article  CAS  PubMed  Google Scholar 

Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 362:2077–2091. https://doi.org/10.1056/NEJMoa0907083

Article  CAS  PubMed  Google Scholar 

Freire-Alvarez E, Kurča E, Lopez Manzanares L et al (2021) Levodopa-carbidopa intestinal gel reduces Dyskinesia in Parkinson’s Disease in a Randomized Trial. Mov Disord 36:2615–2623. https://doi.org/10.1002/mds.28703

Article  CAS  PubMed  PubMed Central  Google Scholar 

Georgiev D, Delalić S, Zupančič Križnar N et al (2022) Switching and combining device-aided therapies in Advanced Parkinson’s Disease: a double Centre Retrospective Study. Brain Sci 12:343. https://doi.org/10.3390/brainsci12030343

Article  PubMed  PubMed Central  Google Scholar 

Geraedts VJ, Feleus S, Marinus J et al (2020) What predicts quality of life after subthalamic deep brain stimulation in Parkinson’s disease? A systematic review. Eur J Neurol 27:419–428. https://doi.org/10.1111/ene.14147

Article  CAS  PubMed  Google Scholar 

Groppa S, Gonzalez-Escamilla G, Tinkhauser G et al (2023) Perspectives of implementation of closed-Loop Deep Brain Stimulation: from neurological to Psychiatric disorders. Stereotact Funct Neurosurg 1–15. https://doi.org/10.1159/000535114

Grund KE, Zipfel A, Duckworth-Mothes B, Jost WH (2023) Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson’s syndrome. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-023-02601-0

Article  PubMed  Google Scholar 

Hacker ML, Meystedt JC, Turchan M et al (2023) Eleven-Year outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease. Neuromodulation 26:451–458. https://doi.org/10.1016/j.neurom.2022.10.051

Article  PubMed  Google Scholar 

Hardoff R, Sula M, Tamir A et al (2001) Gastric emptying time and gastric motility in patients with Parkinson’s disease. Mov Disord 16:1041–1047. https://doi.org/10.1002/mds.1203

Article  CAS  PubMed  Google Scholar 

Hechtner MC, Vogt T, Zöllner Y et al (2014) Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20:969–974. https://doi.org/10.1016/j.parkreldis.2014.06.001

Article  PubMed  Google Scholar 

Honey CR, Hamani C, Kalia SK et al (2017) Deep brain stimulation target selection for Parkinson’s Disease. Can J Neurol Sci 44:3–8. https://doi.org/10.1017/cjn.2016.22

Article  PubMed  Google Scholar 

Jost ST, Sauerbier A, Visser-Vandewalle V et al (2020) A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up. J Neurol Neurosurg Psychiatry 91:687–694. https://doi.org/10.1136/jnnp-2019-322614

Article  PubMed  Google Scholar 

Jost ST, Visser-Vandewalle V, Rizos A et al (2021) Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. NPJ Parkinsons Dis 7:48. https://doi.org/10.1038/s41531-021-00174-x

Article  PubMed  PubMed Central  Google Scholar 

Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759.